Astrazeneca Vaccine Showing 79% Success Rate Against Symptomatic Coronavirus Disease

It’s been announced that in the next few weeks, Astrazeneca is expected to apply for emergency use authorization from the U.S. Food and Drug Administration for it’s Covid-19 vaccine in the U.S. In a new U.S. based clinical trial, the vaccine showed 79% success against symptomatic disease and a 100% success against severe disease and hospitalization. The findings from the new phase 3 trial, which included more than 32,000 participants could boost confidence in the vaccine. The trial was conducted in the U.S., Chile and Peru. 79% of trial participants were White, 22% were Hispanic, 8% were African American, 4% were Native American and 4% were Asian. 20% of participants were 65 years and over and about 60% had conditions linked with higher risk of severe coronavirus such as diabetes, severe obesity or heart disease. According to CDC data, so far, more than 81.4 million Americans have gotten at least one dose of the coronavirus vaccine. Which is roughly 24.5% of the U.S. population and more than 44 million have been fully vaccinated.